Allena Pharmaceuticals is a biopharmaceutical company. Co. focuses on metabolic disorders that result in excess accumulation of certain metabolites that can cause kidney stones, damage the kidney, and lead to chronic kidney disease (CKD) and end-stage renal disease (ESRD). Co.'s main product candidate, reloxaliase, is an oral enzyme therapeutic that it is developing for the treatment of hyperoxaluria, a metabolic disorder characterized by markedly elevated urinary oxalate levels and commonly associated with kidney stones, CKD and ESRD. Co.'s second product candidate, ALLN-346, is an orally administered, urate degrading enzyme for patients with hyperuricemia and gout in the setting of CKD. The ALNA stock yearly return is shown above.
The yearly return on the ALNA stock yearly return page and across the coverage universe of our site,
is a measure of the annual return over the calendar year 2020 for the given stock.
When performing this calculation it is important to factor in dividends, because a financial instrument's annual return is
more than just the change in price if that instrument pays a dividend or coupon.
One way to factor dividends into the return is simply to count them as cash — we don't do
that here. Instead, our website aims to empower investors
by performing the ALNA annual return calculation with any dividends reinvested as applicable (on ex-dates).
|